bluebird bio(BLUE) - 2024 Q3 - Quarterly Results

Exhibit 99.1 bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance - 74 patient starts completed or scheduled to date in 2024 across bluebird's commercial portfolio - - Third quarter 2024 net revenue of $10.6 million reflects quarter-to-quarter fluctuations in drug product infusions; anticipate at least $25 million of net revenue in the fourth quarter - - Management to host conference call today, November 14, 2024 at 8:00 am ET - SOMERVILLE, Mass. – November 1 ...